News

Buy Eris Lifesciences Ltd For Target Rs.710 - Motilal Oswal On an acquisition spree to enhance derma portfolio Deal to be EPS neutral over the medium term * The acquisition of nine brands from Dr. Reddy’s Lab (sales: INR500m for INR2.7b) is the third deal in the dermatology space over the past 12M. * The valuation in terms of EV/sales stands at 5.4x/4.8x for FY23/FY24. This is higher than its earlier acquisitions. * Given that the acquisition is funded through debt, we expect the deal to be earnings neutral over the medium term. Alth...
Buy Eris Lifesciences Ltd For Target Rs.710 - Motilal Oswal
Buy Eris Lifesciences Ltd For Target Rs.710 - Motilal Oswal
Source: Motilal Oswal Financial Services
18/03/2023 11:38:47 AM
Eris Lifesciences trades higher on planning to acquire nine dermatology brands from Dr Reddy`s Laboratories Eris Lifesciences is currently trading at Rs. 590.60, up by 6.80 points or 1.16% from its previous closing of Rs. 583.80 on the BSE. The scrip opened at Rs. 590.45 and has touched a high and low of Rs. 592.20 and Rs. 570.00 respectively. So far 1374 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 749.85 on 06-Oct-2022 and a 52 week low of Rs. 570.00 on 16-Mar-2023. Last one week high and low of the scrip stood a...
Eris Lifesciences trades higher on planning to acquire nine dermatology brands from Dr Reddy`s Laboratories
Eris Lifesciences trades higher on planning to acquire nine dermatology brands from Dr Reddy`s Laboratories
Source: Accord Fintech
17/03/2023 12:17:50 PM
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million Indian drugmaker Eris Lifesciences Ltd said on Thursday it had bought nine dermatology brands from Dr. Reddy's Laboratories Ltd in a 2.75 billion rupees ($33.24 million) deal, to expand in the cosmetic dermatology business. The deal, to be paid in cash, is expected to be completed on or before March 31, Eris said in a stock exchange filing. Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands. The deal comes two...
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million
Source: Reuters
16/03/2023 3:15:53 PM
Eris Life Sciences : Launches and Oaknet to drive growth; retaining a Buy - Anand Rathi Share and Stock Brokers Driven by standalone growth (14% to Rs3.5bn) and Oaknet’s contribution (Rs681m), Eris’ Q2 revenue grew 28% y/y to Rs4.6bn. The pick-up in recent launches would improve gross margins (now 77%). Higher employee and other expenses compressed the EBITDA margin to 32.9%. Amortisation for Oaknet led to flat profits of Rs1.2bn. The ramp-up in the Oaknet portfolio, insulin products and launches would drive 20%/19%/8% revenue/EBITDA/PAT CAGRs. We retain our Buy rating, with a lower TP of R...
Eris Life Sciences : Launches and Oaknet to drive growth; retaining a Buy - Anand Rathi Share and Stock Brokers
Eris Life Sciences : Launches and Oaknet to drive growth; retaining a Buy - Anand Rathi Share and Stock Brokers
Source: Anand Rathi Share and Stock Brokers
26/10/2022 12:18:00 PM
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal Niche launches to aid growth over the medium term Promising start for Drolute and Xsulin * The Dydrogesterone market is at an interesting phase, with an improvement in demand due to better access, affordability, and technical superiority over Progesterone.  The initial response for ERIS’ product (Drolute) has been encouraging, with sales of INR44m since its launch in Jan’22. We expect this product to aid 2-3% YoY growth for ERIS in FY23. * While the Insulin market has be...
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
24/05/2022 11:26:08 AM
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal In line 4QFY22 at the operational level; geared up for launches in FY23 Specialty segment gets a boost from the Oaknet acquisition ERIS delivered an operationally inline 4QFY22. It ended the second consecutive year with earnings growth in the a healthy teens compared to stable earnings over FY18-20. The acquisition of Oaknet Healthcare (Oaknet) enables ERIS to add a Dermatology franchise, expand into the Cosmetology space, and improve synergy in the Women’s Healthcare segment. ...
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal
Buy Eris Lifesciences Ltd For Target Rs.870 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
5/05/2022 11:23:37 AM
Buy Eris Lifesciences Ltd For Target Rs 870 - Motilal Oswal The Pharma Brand Master Mix of Chronic portfolio, rising coverage, and better operating leverage to drive earnings growth * We initiate coverage on Eris Lifesciences (ERIS) with a BUY rating and a target price of INR870. In just 14 years (founded in CY07), ERIS has built a pure-play Branded Formulation business, with a revenue of INR13b (12M ending Sep’21). Notably, its PAT has nearly doubled to INR3.5b during FY16–21. * ERIS ranks among the Top 25 Indian companies i...
Buy Eris Lifesciences Ltd For Target Rs 870 - Motilal Oswal
Buy Eris Lifesciences Ltd For Target Rs 870 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
28/12/2021 9:54:41 AM
Eris Lifesciences Q4 net profit up 27.06% at Rs 69.35 cr The company reported standalone net profit of Rs 69.35 crore for the quarter ended March 31, 2021 as compared to Rs 54.58 crore in the same period last year, registering a year-on-year growth of 27.06 per cent. Net revenue of the company rose moderately by 13.61 per cent at Rs 256.85 crore in January-March quarter of this fiscal as against Rs 226.08 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 3.31 per cent to Rs 162.83 crore fr...
Eris Lifesciences Q4 net profit up 27.06% at Rs 69.35 cr
Eris Lifesciences Q4 net profit up 27.06% at Rs 69.35 cr
Source: Dion Global Solutions Ltd
14/05/2021 11:02:05 AM